Corrigendum

This corrigendum lists the corrections for the research letter titled Paradigm shift in the treatment of bladder cancer? The Swedish perspective, written by Per-Uno Malmström and Eugen Y.H. Wang (2025). Published in Scandinavian Journal of Urology, Volume 60, NO.1, 186–188, DOI: https://doi.org/10.2340/sju.v60.44464.

 

 

Citation: Scandinavian Journal of Urology 2026, VOL. 61, 7. https://doi.org/10.2340/sju.v61.45153.

Copyright: © 2025 The Author(s). Published by MJS Publishing on behalf of Acta Chirurgica Scandinavica. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.

Published: 13 January 2026

 

Location Error Correction
1. p. 2,Title section Muscle-invasive bladder cancer. Nevertheless, NAC utilization in Sweden declined, after an initial period of enthusiasm, with 10% between 2015 and 2023, as shown in Figure 2. Earlier data showed a decline in the use of NAC in Sweden (Figure 2) while later in a more complete dataset, the share of patients under 75 years of age receiving neoadjuvant treatment before surgery is stable at 39–44%, with an increasing trend among those who undergo cystectomy.
2. p.1, Abstract, section 3, row 5 While extended dissection has not shown clear survival benefits, NAC improves 5-year survival by 8%, yet its utilization has declined. Extended dissection has not shown clear survival benefits. NAC improves 5-year survival by 8% and is used in about half of Swedish patients.